These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10916053)

  • 1. [Economic aspects of Parkinson disease treatment].
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():215-6. PubMed ID: 10916053
    [No Abstract]   [Full Text] [Related]  

  • 2. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease.
    Green AL; Joint C; Sethi H; Bain P; Aziz TZ
    J Clin Neurosci; 2004 Nov; 11(8):829-34. PubMed ID: 15519857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
    Charles PD; Padaliya BB; Newman WJ; Gill CE; Covington CD; Fang JY; So SA; Tramontana MG; Konrad PE; Davis TL
    Parkinsonism Relat Disord; 2004 Dec; 10(8):475-9. PubMed ID: 15542007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Accessibility to the specific pharmacotherapy for Parkinson disease, in Santiago de Chile].
    Chaná P; Galdames D
    Rev Med Chil; 1998 Nov; 126(11):1355-61. PubMed ID: 10349179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct costs of managing Parkinson's disease in India: concerns in a developing country.
    Ragothaman M; Govindappa ST; Rattihalli R; Subbakrishna DK; Muthane UB
    Mov Disord; 2006 Oct; 21(10):1755-8. PubMed ID: 16874759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.
    Schüpbach WM; Maltête D; Houeto JL; du Montcel ST; Mallet L; Welter ML; Gargiulo M; Béhar C; Bonnet AM; Czernecki V; Pidoux B; Navarro S; Dormont D; Cornu P; Agid Y
    Neurology; 2007 Jan; 68(4):267-71. PubMed ID: 17151341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
    Dengler I; Leukel N; Meuser T; Jost WH
    Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patients with Parkinson disease: help in management of the disease].
    Späte HF; Gemende I; Gemende G
    Z Arztl Fortbild (Jena); 1988; 82(21):1081-3. PubMed ID: 3247791
    [No Abstract]   [Full Text] [Related]  

  • 15. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does subthalamic nucleus deep brain stimulation really improve quality of life in Parkinson's disease?
    Gronchi-Perrin A; Viollier S; Ghika J; Combremont P; Villemure JG; Bogousslavsky J; Burkhard PR; Vingerhoets F
    Mov Disord; 2006 Sep; 21(9):1465-8. PubMed ID: 16763974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study.
    Visser-Vandewalle V; van der Linden C; Temel Y; Celik H; Ackermans L; Spincemaille G; Caemaert J
    Parkinsonism Relat Disord; 2005 May; 11(3):157-65. PubMed ID: 15823480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.